HC Wainwright Issues Optimistic Outlook for ATRA Earnings

Atara Biotherapeutics, Inc. (NASDAQ:ATRAFree Report) – Equities researchers at HC Wainwright increased their Q2 2025 earnings per share (EPS) estimates for shares of Atara Biotherapeutics in a report released on Tuesday, January 28th. HC Wainwright analyst R. Burns now expects that the biotechnology company will post earnings per share of ($4.04) for the quarter, up from their prior forecast of ($4.15). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Atara Biotherapeutics’ current full-year earnings is ($9.86) per share. HC Wainwright also issued estimates for Atara Biotherapeutics’ Q4 2025 earnings at ($3.59) EPS and FY2025 earnings at ($8.41) EPS.

A number of other analysts have also recently commented on the company. Canaccord Genuity Group cut their price objective on Atara Biotherapeutics from $21.00 to $17.00 and set a “buy” rating for the company in a research report on Friday, January 17th. RODMAN&RENSHAW downgraded shares of Atara Biotherapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 21st. TD Cowen raised shares of Atara Biotherapeutics to a “strong-buy” rating in a research note on Friday, November 29th. Finally, Rodman & Renshaw began coverage on shares of Atara Biotherapeutics in a research note on Friday, December 20th. They issued a “buy” rating and a $25.00 target price on the stock. One analyst has rated the stock with a sell rating, three have given a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $17.75.

View Our Latest Research Report on Atara Biotherapeutics

Atara Biotherapeutics Trading Up 4.9 %

Atara Biotherapeutics stock opened at $8.49 on Thursday. The firm has a market cap of $48.90 million, a PE ratio of -0.33 and a beta of 0.51. Atara Biotherapeutics has a 12 month low of $5.40 and a 12 month high of $39.50. The stock’s 50 day simple moving average is $11.74 and its two-hundred day simple moving average is $9.92.

Atara Biotherapeutics (NASDAQ:ATRAGet Free Report) last issued its earnings results on Tuesday, November 12th. The biotechnology company reported ($2.93) EPS for the quarter, beating analysts’ consensus estimates of ($3.77) by $0.84. The firm had revenue of $40.19 million during the quarter, compared to analysts’ expectations of $23.00 million. During the same quarter in the prior year, the company earned ($16.50) EPS.

Institutional Trading of Atara Biotherapeutics

Several hedge funds have recently made changes to their positions in the company. Cubist Systematic Strategies LLC purchased a new stake in Atara Biotherapeutics in the 2nd quarter valued at about $79,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Atara Biotherapeutics during the second quarter valued at about $53,000. FMR LLC raised its stake in shares of Atara Biotherapeutics by 41.7% in the 3rd quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock valued at $204,000 after acquiring an additional 7,381 shares during the period. Vestal Point Capital LP lifted its holdings in shares of Atara Biotherapeutics by 11.3% in the 3rd quarter. Vestal Point Capital LP now owns 124,677 shares of the biotechnology company’s stock worth $1,014,000 after acquiring an additional 12,677 shares during the last quarter. Finally, State Street Corp lifted its holdings in shares of Atara Biotherapeutics by 52.3% in the 3rd quarter. State Street Corp now owns 22,353 shares of the biotechnology company’s stock worth $182,000 after acquiring an additional 7,680 shares during the last quarter. Hedge funds and other institutional investors own 70.90% of the company’s stock.

Atara Biotherapeutics Company Profile

(Get Free Report)

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.

Read More

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.